Clinical Trial Update: Inhibiting the Anti-apoptotic Factor, BCL-2, at the Time of ART Initiation to Promote Apoptosis of HIV-infected Cells and Restrict the Seeding of the HIV Reservoir: An Investigator-initiated Randomised, Controlled, Open-label Clinical Trial (The INITIATE Study) [Phase 1]

View source ↗

Summary

An investigator-initiated Phase 1 randomized, open-label trial evaluating inhibiting BCL-2 at ART initiation to promote apoptosis of HIV-infected cells and limi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Snippet

Sponsor: Thomas Aagaard Rasmussen | Conditions: HIV-1 | Phase 1 | Status: NOT_YET_RECRUITING